Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
ID: 359002Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359002

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-25-014.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional). This funding opportunity aims to support investigator-initiated clinical trials that advance regenerative medicine, particularly using adult stem cells, as outlined by the 21st Century Cures Act. The initiative is crucial for enhancing research on regenerative therapies and addressing barriers in clinical development, with a total funding amount of up to $3.5 million available, and a maximum of $400,000 in direct costs per year for each awarded project. Interested applicants must submit their proposals by October 21, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the opportunity's webpage for more details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AR-25-014-Full-Announcement.html
    RFA-AR-25-014.html
    The National Institutes of Health (NIH) is soliciting applications for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) under the UH3 Exploratory/Developmental Cooperative Agreement Phase II. This funding opportunity seeks renewal applications from investigator-initiated clinical trials that aim to advance regenerative medicine using adult stem cells, as established by the 21st Century Cures Act. Eligible organizations include various educational institutions, non-profits, and for-profit entities. Notably, applicants are required to match federal funding on a 1:1 basis with non-federal contributions. Key project goals include enhancing research on regenerative therapies and overcoming existing barriers in clinical development. The NIH emphasizes the significance of projects that provide valuable data following previous RMIP trials. The expected funding totals up to $3.5 million, with a maximum of $400,000 in direct costs per year per awarded project, and the application period runs through October 22, 2025. NIH grants policies apply, including strict adherence to application guidelines and requirements for sharing data generated from the projects. Applications will be evaluated based on scientific merit, approach, and investigator qualifications, ensuring a focused enhancement of regenerative medicine's impact on health.
    Similar Opportunities
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at supporting preclinical research using adult stem cells. This initiative invites current recipients of prior RMIP grants to submit renewal applications that focus on late-stage preclinical studies, enhancing the development of safe and effective regenerative medicine therapies while addressing critical regulatory issues and promoting data sharing. The NIH plans to allocate up to $3.5 million in federal funds, with a requirement for successful applicants to match these funds with non-federal contributions on a 1:1 basis, as mandated by the 21st Century Cures Act. Interested applicants must adhere to specific guidelines and demonstrate significant collaboration with NIH staff, with applications due by October 21, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-25-013.html.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for competitive revisions to support clinical trials in somatic cell genome editing, specifically under the funding opportunity RFA-RM-24-008. This initiative aims to expand the existing Somatic Cell Genome Editing program by soliciting applications from awardees with active U19 awards funded under RFA-RM-22-015, which previously did not allow clinical trials. The funding will facilitate first-in-human genome editing clinical trials, including essential preparatory activities such as patient recruitment, regulatory approvals, and the development of clinical trial designs. Interested applicants must submit their proposals by February 13, 2026, and can find additional information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NCMRR Early Career Research Award (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCMRR Early Career Research Award (R03 Clinical Trial Optional) to support rehabilitation scientists in establishing independent research careers. This grant aims to fund basic and clinical research projects that align with the mission of the National Center for Medical Rehabilitation Research (NCMRR), encouraging innovative studies in areas such as secondary data analysis, translational research, and the development of new technologies. The total estimated program funding is $200,000, with an award ceiling of $200,000, and applications are due by January 7, 2028. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.